# Women's health telehealth, under your brand

Source: https://myorbithealth.com/solutions/womens-health

MyOrbitHealth is the women's health telehealth platform behind branded menopause, contraception, PCOS and hair and skin programs. You own the brand, the patients, the pricing and the checkout. MyOrbitHealth supplies the parts a brand cannot legally run on its own: 2,400+ board-certified providers licensed across all 50 states and 38+ specialties, Orbit Intake for menopause and contraception screening, OrbitRx e-prescribing via Surescripts to a LegitScript-certified network of 503A compounding and retail pharmacies, and Orbit Labs for the hormone, thyroid and metabolic panels a perimenopause or PCOS plan depends on. Providers respond in under six minutes on average during business hours, coverage is 24 hours, and every contract carries HIPAA and a BAA. The FDA's February 2026 label changes removed most boxed warnings from menopausal hormone therapy, which has moved online menopause treatment from a niche into a mainstream category. Commercially there is a flat platform fee scoped at onboarding, 0% medication markup, no revenue share, no exit fee and month-to-month terms after onboarding. Programs typically go live in days. This page is general information, not legal or medical advice, and regulatory points are stated as of September 2026.

## Who runs what

A women's health program has two halves: the brand and the clinic. You run the brand. MyOrbitHealth runs the clinical, pharmacy, lab and compliance infrastructure so the program operates the way a licensed practice does. The split below is the one we put in every contract.

- **Brand, marketing and pricing:** You: own the brand, the storefront design, ad creative, membership pricing and the patient relationship. / MyOrbitHealth: supplies the branded storefront with checkout and subscriptions and the native iOS and Android app, with no MyOrbitHealth logo in front of the patient.
- **Program menu and launch states:** You: choose which programs to offer (menopause and perimenopause, contraception, PCOS and metabolic, hair and skin) and which states to launch first. / MyOrbitHealth: confirms provider coverage by state and specialty and stages each program so the first one can be live in days.
- **Intake and screening:** You: approve the patient-facing copy and the questions that appear in your funnel. / MyOrbitHealth: runs Orbit Intake with condition-specific questionnaires, identity verification, state routing and the contraindication screens a provider needs before a first visit, including migraine with aura, clotting history, blood pressure and breast cancer history.
- **Hormone and metabolic labs:** You: decide which panels appear on the storefront and whether patients can self-order from the lab catalog. / MyOrbitHealth: Orbit Labs issues provider-ordered requisitions, offers Quest or Labcorp walk-in, Tasso at-home kits shipped by FedEx, or mobile phlebotomy, and routes results to the ordering provider.
- **Diagnosis and prescribing:** You: never touch a clinical decision. / MyOrbitHealth: a provider licensed in the patient's state reviews symptoms, history and any labs, decides whether treatment is appropriate, chooses the product and dose, and prescribes through OrbitRx.
- **Pharmacy and fulfillment:** You: set the product menu with your medical director (estradiol patches, gels and tablets, micronized progesterone, vaginal estrogen, combined and progestin-only pills, spironolactone, topical minoxidil, tretinoin, metformin). / MyOrbitHealth: routes each prescription via Surescripts to a LegitScript-certified 503A compounding or retail pharmacy, with cold chain where the product requires it.
- **Compliance and credentialing:** You: keep your corporate entity, merchant account and marketing claims in order. / MyOrbitHealth: runs NCQA-standard primary-source credentialing with monthly OIG and SAM screening, SOC 2 Type II and HITRUST-aligned controls, HIPAA with a BAA, and managed LegitScript certification for your brand.

## What a women's health program requires, clinically and legally

Women's health is several programs under one roof, and each one has its own clinical rules. The points below are the ones that shape how we build intake, prescribing and follow-up. They are general information as of September 2026, not legal or medical advice, and your medical director and counsel make the final call.

- **Menopausal hormone therapy after the 2026 label changes** — In November 2025 the FDA announced it would remove the boxed warnings for cardiovascular disease, breast cancer and probable dementia from menopausal hormone therapy products, and the approved labeling changes were published in February 2026. The updated labels cite evidence that women who start systemic therapy within 10 years of menopause onset, generally before 60, see reductions in all-cause mortality and fractures. What did not change: estrogen-alone products still carry the endometrial cancer warning, so a patient with a uterus still needs a progestogen alongside systemic estrogen. A provider still has to take a history, screen for contraindications such as undiagnosed vaginal bleeding, active breast cancer or a clotting history, and document the discussion. The label change lowers the marketing friction; it does not lower the clinical bar.
- **Perimenopause is a clinical diagnosis, labs are supporting evidence** — Menopause societies have said for years that perimenopause is diagnosed by age, cycle changes and symptoms, not by a single FSH value, because hormone levels swing from week to week. That matters for how a program is built. A provider on the MyOrbitHealth network will treat symptoms, not a number, and will order labs where they change the plan: thyroid function to rule out an alternative cause, a lipid panel and A1c before starting therapy in a patient with metabolic risk, or an estradiol level when adjusting a transdermal dose. A program that promises a hormone panel as the gate to treatment tends to over-test and under-treat. A program that never tests misses thyroid disease and diabetes. Orbit Labs sits in the middle: provider-ordered, read into the plan, never a sales tool.
- **FDA-approved hormones vs compounded hormones** — FDA-approved estradiol and micronized progesterone are the default for most menopause plans, and they are covered by the new labeling. Compounded bioidentical hormone therapy, including pellets, is a different category. A National Academies report recommended limiting compounded hormones to patients who cannot use an approved product, for example because of an allergy to an excipient or a need for a dosage form that does not exist commercially. As of September 2026 the FDA has nominated several compounded hormone ingredients, including estradiol, estriol, progesterone and testosterone, for review under the demonstrably difficult to compound process, and the outcome is not final. Our position is practical: OrbitRx routes to both 503A compounding and retail pharmacies, your medical director sets the protocol, and the program should be designed so that it still works if compounded hormones are restricted.
- **Contraception by telehealth** — Hormonal contraception is one of the best-established telehealth use cases. Self-reported blood pressure, a migraine and clotting history and a smoking screen are the core of a safe prescription, and the CDC's eligibility criteria give a provider a clear framework. The landscape has shifted around it: Opill is available over the counter, and as of September 2026 roughly 30 states plus DC allow pharmacists to prescribe contraceptives. That means a brand's contraception program has to earn its place with convenience, continuity and bundling (skin, hair, cycle tracking) rather than access alone. Extended-supply dispensing, which many states now require insurers to cover, is a natural fit for subscriptions. Prescription-only methods such as the ring, the patch and drospirenone-only pills stay squarely in the provider's lane.
- **PCOS and metabolic care** — PCOS affects an estimated one in ten women of reproductive age and is diagnosed on a combination of irregular cycles, clinical or biochemical hyperandrogenism and ultrasound findings, with other causes excluded. The 2023 international guideline update supports metformin, combined oral contraceptives and lifestyle care as first-line options depending on the patient's goals, and off-label GLP-1 use for weight in PCOS is increasingly common. A telehealth PCOS program therefore needs labs (total and free testosterone, TSH, prolactin, A1c, lipids), a provider who will manage a chronic condition over months and a pharmacy network that can fill both retail and compounded products. Any GLP-1 prescribing should be handled under the same rules as a weight-loss program, which is why many brands pair this page with the GLP-1 solution.
- **Hair and skin as prescription programs** — Female pattern hair loss, hormonal acne and melasma are large categories where the products are prescription-only (oral spironolactone, oral minoxidil off-label, tretinoin, hydroquinone, azelaic acid) and the visit is asynchronous. Photo-based intake works, but the provider still needs a medical history: spironolactone requires a pregnancy discussion and, in some patients, potassium monitoring; oral minoxidil requires a blood pressure and cardiac screen; tretinoin and hydroquinone carry pregnancy cautions. These programs are low-touch clinically and high-value commercially, and they are the usual second product for a menopause or contraception brand.

## What MyOrbitHealth runs for your women's health program

Every product below is white-labeled. The patient sees your brand, your pricing and your app. The clinical and pharmacy layer underneath is MyOrbitHealth, and it already powers 50+ digital clinics.

- **Provider Network: 2,400+ providers, all 50 states, 38+ specialties** — Women's health programs need providers who are comfortable with hormone therapy, contraception and dermatology, not a generic urgent-care roster. The network includes OB-GYN, family medicine, internal medicine, endocrinology and dermatology, credentialed to NCQA standards with primary-source verification and monthly OIG and SAM screening. Response time is under six minutes on average during business hours with 24-hour availability, which is what a same-day contraception or menopause consult needs.
- **Orbit Intake: condition-specific screening** — Orbit Intake ships with questionnaires for menopause and perimenopause (symptom score, cycle history, bleeding, breast and clotting history), contraception (CDC eligibility screens, blood pressure, migraine with aura, smoking), PCOS (cycle pattern, hyperandrogenism, weight history) and hair and skin (photo upload, pregnancy status, prior treatments). Identity verification and state routing happen before the provider sees the case. You approve the copy; the clinical logic is ours.
- **OrbitRx: e-prescribing to compounding and retail pharmacies** — OrbitRx sends every prescription via Surescripts to a LegitScript-certified network that includes 503A compounding pharmacies and retail pharmacies, with cold chain where a product requires it. EPCS with two-factor identity proofing is built in for the rare controlled substance in a women's health program. Estradiol, progesterone, contraceptives, spironolactone, minoxidil, tretinoin and metformin route to the pharmacy that fills them at the best turnaround, and the medication is passed through at 0% markup.
- **Orbit Labs: hormone, thyroid and metabolic panels** — Orbit Labs lets the provider order the panel the plan actually needs: FSH and estradiol where useful, TSH and free T4, total and free testosterone, prolactin, A1c, lipids, potassium for spironolactone patients and a CBC where indicated. Patients can be drawn three ways: a Quest or Labcorp walk-in order slip, a Tasso at-home kit shipped by FedEx, or mobile phlebotomy at home. Results come back to the ordering provider and are read into the plan, and you can also expose a self-order lab catalog on the storefront for patients who want a baseline before they book.
- **Patient Portal, Storefront and App** — The branded storefront handles checkout, subscriptions and refills, with the patient portal and a native iOS and Android app for messaging, photo updates, lab results and plan changes. Subscriptions map cleanly to how women's health is bought: monthly hormone therapy, three-month contraception supplies, quarterly hair and skin refills. You are the merchant of record, and you own the patients and the data.
- **API, SDK, webhooks and MCP server** — If you already have a front end, the REST API, webhooks and React SDK let you keep it and plug in intake, provider review, prescribing and labs behind it. A public MCP server exposes the same capabilities to agent workflows. Managed LegitScript certification runs alongside: we prepare, file and manage your brand's application through approval, typically days once filed, with the decision resting with LegitScript.

## Economics and where the program can go next

The commercial model is the same for every program on the platform. There is no revenue share and no medication markup, so the margin on a menopause or contraception subscription is yours to price.

- **Platform fee:** A flat platform fee scoped at onboarding. It covers the provider network, Orbit Intake, OrbitRx, Orbit Labs, the storefront and app, credentialing and compliance. No per-visit surprises.
- **Medication and labs:** 0% medication markup and no revenue share on anything the patient buys. Orbit Labs panels are provider-ordered or self-ordered from the storefront catalog, and you set the retail price on your storefront.
- **Ownership:** You are the merchant of record. You own the patients, the data and the brand relationship. There is no exit fee, and after onboarding the contract runs month-to-month.
- **Time to launch:** Programs typically go live in days. Menopause and contraception are usually first because intake and provider coverage are already built; hair, skin and PCOS follow as the brand grows.
- **Expansion path:** Start with online menopause treatment, add vaginal estrogen and sleep or mood support, then contraception for a younger cohort, then hair and skin as add-ons for both. PCOS and GLP-1 weight management can run on the same stack under the GLP-1 solution.
- **What the platform does not do:** MyOrbitHealth does not run your marketing, your ad accounts or your pricing tests, and it does not make clinical decisions on your behalf. The providers do, and their independence is what keeps the program compliant.

## FAQ

### Can menopause hormone therapy be prescribed by telehealth in 2026?
Yes, in every state, as of September 2026. Estradiol and progesterone are not controlled substances, and the FDA's February 2026 labeling changes removed the boxed warnings for cardiovascular disease, breast cancer and dementia from menopausal hormone therapy. A licensed provider still needs a history, a contraindication screen and documentation of the discussion, and estrogen-alone products still carry an endometrial cancer warning. This is general information, not legal or medical advice.

### Do patients need a hormone panel before starting menopause treatment?
Not as a gate. Perimenopause and menopause are diagnosed clinically, and menopause societies advise against relying on a single FSH value. Providers on the network order labs where they change the plan, such as thyroid function, A1c and lipids, and Orbit Labs makes that a walk-in, at-home kit or mobile draw. Brands can also offer a self-order lab catalog on the storefront.

### Can the program prescribe compounded bioidentical hormones or pellets?
OrbitRx routes to both 503A compounding and retail pharmacies, so the option exists. Whether a provider uses it is a clinical decision under your medical director's protocol. As of September 2026 the FDA is reviewing several compounded hormone ingredients under the demonstrably difficult to compound process, so we recommend building the program around FDA-approved products first and treating compounded options as the exception.

### Does the platform support online birth control programs?
Yes. Orbit Intake runs the CDC-based eligibility screen, a provider reviews it and prescribes combined or progestin-only pills, the patch or the ring through OrbitRx, and the storefront handles three-month and twelve-month supplies on subscription. Note that Opill is now over the counter and many states allow pharmacist prescribing, so most brands bundle contraception with skin, hair or cycle support.

### Can I run PCOS, hair loss and acne on the same platform?
Yes. The same provider network, intake, OrbitRx and Orbit Labs run PCOS (metformin, combined pills, spironolactone, labs), female pattern hair loss (oral and topical minoxidil, spironolactone) and acne or melasma (tretinoin, azelaic acid, hydroquinone). GLP-1 prescribing for PCOS follows the rules of our GLP-1 weight-loss solution.

### What does a women's health telehealth platform cost?
A flat platform fee scoped at onboarding, 0% medication markup, no revenue share and no exit fee. After onboarding the contract is month-to-month. You are the merchant of record and set your own retail pricing. We do not publish a figure because the fee is scoped to the programs and states you launch.

## Launch a women's health program under your brand

Menopause, contraception, PCOS and hair and skin programs with 2,400+ providers in all 50 states, Orbit Labs for hormone panels and a LegitScript-certified pharmacy network. Flat platform fee, 0% markup, live in days.

Book a call: https://myorbithealth.com/book

Go deeper: [how to launch a women's health brand](https://myorbithealth.com/blog/launch-womens-health-brand), [online menopause treatment: what a program needs](https://myorbithealth.com/blog/online-menopause-treatment), [the MSO model for telehealth compliance](https://myorbithealth.com/blog/telehealth-compliance-mso-model-guide)